NVIDIA has secured Eli Lilly, Thermo Fisher Scientific, and Tetrascience as anchor partners for BioNeMo, its AI platform for drug discovery, establishing dominance across pharmaceutical markets in North America, Europe, and Asia.1 The coordinated deals create a vertically integrated system spanning pharmaceutical R&D, laboratory equipment, and data processing used by biotech firms globally.
BioNeMo provides pre-trained AI models for molecular structure prediction, protein design, and drug-target interaction analysis.1 Lilly will deploy the platform across its research facilities, while Thermo Fisher—which supplies lab equipment to pharmaceutical companies worldwide—integrates BioNeMo directly into instrument workflows.1
Tetrascience's data platform now channels experimental results straight into BioNeMo models, eliminating separate data infrastructure.1 This integration compels biotech companies across markets to adopt NVIDIA's stack or invest heavily in alternatives.
Six AI-focused biotech firms spanning three continents have launched foundation models on BioNeMo: Terray Therapeutics, Apheris, Basecamp Research, Owkin, Boltz Lab, and Edison Scientific.1 Each contributes specialized models while relying on BioNeMo's architecture, strengthening network effects across the global pharmaceutical industry.
The strategy replicates NVIDIA's approach in autonomous vehicles and robotics—provide subsidized infrastructure, then capture recurring revenue through compute sales and licensing as adoption scales. Pharmaceutical companies face identical calculus worldwide: build proprietary AI stacks at high cost or accept vendor lock-in.
Thermo Fisher's role is particularly strategic. The company supplies lab equipment to major pharmaceutical and biotech firms across North America, Europe, and Asia-Pacific. Embedding BioNeMo into these instruments makes NVIDIA's AI the default for millions of experiments annually across global markets.
The timing exploits worldwide pharmaceutical urgency around AI adoption. Traditional drug discovery takes 10-15 years and costs over $2 billion per approved drug. AI promises to cut both timelines and costs, creating pressure to adopt platforms with the largest datasets—advantages BioNeMo is accumulating through these international partnerships.
